These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 11359038)

  • 1. Bronchopulmonary dysplasia and surfactant.
    Bancalari E; del Moral T
    Biol Neonate; 2001 May; 80 Suppl 1():7-13. PubMed ID: 11359038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhalation or instillation of steroids for the prevention of bronchopulmonary dysplasia.
    Bassler D
    Neonatology; 2015; 107(4):358-9. PubMed ID: 26044104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [From classic to new bronchopulmonary dysplasia].
    Kramer BW; Lievense S; Been JV; Zimmermann LJ
    Ned Tijdschr Geneeskd; 2010; 154():A1024. PubMed ID: 20456770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compare severity of bronchopulmonary dysplasia in neonates with respiratory distress syndrome treated with surfactant to without surfactant.
    Chotigeat U; Ratchatanorravut S; Kanjanapattanakul W
    J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S35-40. PubMed ID: 22043752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bronchopulmonary dysplasia].
    Clément A
    Rev Mal Respir; 1996 Jul; 13(3):243-9. PubMed ID: 8765916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratracheal Administration of Budesonide/Surfactant to Prevent Bronchopulmonary Dysplasia.
    Yeh TF; Chen CM; Wu SY; Husan Z; Li TC; Hsieh WS; Tsai CH; Lin HC
    Am J Respir Crit Care Med; 2016 Jan; 193(1):86-95. PubMed ID: 26351971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratracheal Administration of Budesonide-Surfactant in Prevention of Bronchopulmonary Dysplasia in Very Low Birth Weight Infants: A Systematic Review and Meta-Analysis.
    Venkataraman R; Kamaluddeen M; Hasan SU; Robertson HL; Lodha A
    Pediatr Pulmonol; 2017 Jul; 52(7):968-975. PubMed ID: 28165675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants.
    Moya FR; Gadzinowski J; Bancalari E; Salinas V; Kopelman B; Bancalari A; Kornacka MK; Merritt TA; Segal R; Schaber CJ; Tsai H; Massaro J; d'Agostino R;
    Pediatrics; 2005 Apr; 115(4):1018-29. PubMed ID: 15805380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome.
    Sinha SK; Lacaze-Masmonteil T; Valls i Soler A; Wiswell TE; Gadzinowski J; Hajdu J; Bernstein G; Sanchez-Luna M; Segal R; Schaber CJ; Massaro J; d'Agostino R;
    Pediatrics; 2005 Apr; 115(4):1030-8. PubMed ID: 15805381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Less invasive surfactant administration is associated with improved pulmonary outcomes in spontaneously breathing preterm infants.
    Göpel W; Kribs A; Härtel C; Avenarius S; Teig N; Groneck P; Olbertz D; Roll C; Vochem M; Weller U; von der Wense A; Wieg C; Wintgens J; Preuss M; Ziegler A; Roth B; Herting E;
    Acta Paediatr; 2015 Mar; 104(3):241-6. PubMed ID: 25474712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal ventilatory strategies and surfactant to protect the preterm lungs.
    Ramanathan R
    Neonatology; 2008; 93(4):302-8. PubMed ID: 18525214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis of bronchopulmonary dysplasia.
    Chess PR; D'Angio CT; Pryhuber GS; Maniscalco WM
    Semin Perinatol; 2006 Aug; 30(4):171-8. PubMed ID: 16860156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of surfactant replacement therapy for preterm neonates with respiratory distress syndrome in low- and middle-income countries: a systematic review.
    Sankar MJ; Gupta N; Jain K; Agarwal R; Paul VK
    J Perinatol; 2016 May; 36 Suppl 1(Suppl 1):S36-48. PubMed ID: 27109091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of combined administration of surfactant and intratracheal budesonide compared to surfactant alone on bronchopulmonary dysplasia (BPD) and mortality rate in preterm infants with respiratory distress syndrome: a single-blind randomized clinical trial.
    Marzban A; Mokhtari S; Tavakkolian P; Mansouri R; Jafari N; Maleki A
    BMC Pediatr; 2024 Apr; 24(1):262. PubMed ID: 38643076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of lung surfactant therapy on chronic lung diseases in premature infants.
    Hudak BB; Egan EA
    Clin Perinatol; 1992 Sep; 19(3):591-602. PubMed ID: 1526073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early regular versus late selective poractant treatment in preterm infants born between 25 and 30 gestational weeks: a prospective randomized multicenter study.
    Dilmen U; Özdemir R; Tatar Aksoy H; Uras N; Demirel N; Kırimi E; Erdeve Ö; Özer E; Baş AY; Gürsoy T; Zenciroğlu A; Ovalı F; Oğuz ŞS
    J Matern Fetal Neonatal Med; 2014 Mar; 27(4):411-5. PubMed ID: 23795582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic versus Early Rescue Surfactant Treatment in Preterm Infants Born at Less than 30 Weeks Gestation or with Birth Weight Less than or Equal 1,250 Grams.
    Chun J; Sung SI; Ho YH; Kim J; Park GY; Yoon SA; Ahn SY; Chang YS; Park WS
    J Korean Med Sci; 2017 Aug; 32(8):1288-1294. PubMed ID: 28665065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surfactant replacement in preterm infants with respiratory distress syndrome.
    Dani C
    Acta Biomed; 2012; 83 Suppl 1():17-20. PubMed ID: 23029871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of intratracheal administration of budesonide combined with pulmonary surfactant in preventing bronchopulmonary dysplasia: a prospective randomized controlled trial.
    Liu MM; Ji L; Dong MY; Zhu XF; Wang HJ
    Zhongguo Dang Dai Er Ke Za Zhi; 2022 Jan; 24(1):78-84. PubMed ID: 35177180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypocarbia before surfactant therapy appears to increase bronchopulmonary dysplasia risk in infants with respiratory distress syndrome.
    Garland JS; Buck RK; Allred EN; Leviton A
    Arch Pediatr Adolesc Med; 1995 Jun; 149(6):617-22. PubMed ID: 7767415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.